The company has reported positive clinical results in conjunction with expanded enrollment in the OCCLUDE I post-market surveillance study.
The Medical University of Lublin, Poland, Department of Interventional Radiology and Neuroradiology reported successful results for 11 cases over a two-day period.
In conjunction with the study, four female patients were treated for pelvic congestion syndrome and seven male patients were treated for varicoceles using the ArtVentive EOS device.
ArtVentive Medical president and chief technology officer Dr Leon Rudakov said: "The OCCLUDE I venous and OCCLUDE II arterial post-market surveillance studies will compound our growing knowledge of the efficacy of the ArtVentive EOS device in vascular embolization treatments, expanding the already strong clinical application for the ArtVentive EOS system.
"Approximately eighty patients will be enrolled at up to ten study sites worldwide in the coming months."
The ArtVentive EOS is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network.
Designed to serve as a safe and reliable alternative to major surgery in certain cases, the ArtVentive EOS serves as a proprietary technology platform for several major clinical areas, including peripheral and neurological vascular disorders, women’s health, interventional cardiology, pulmonary and interventional oncology procedures.
